RNAZ Transcode Therapeutics Inc
Price (delayed)
$0.3688
Market cap
$6.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$98.22
Enterprise value
$3.24M
Highlights
The EPS has soared by 93% YoY and by 59% QoQ
Transcode Therapeutics's debt has plunged by 66% YoY and by 33% from the previous quarter
Transcode Therapeutics's net income has decreased by 5% from the previous quarter but it has increased by 3.6% YoY
Transcode Therapeutics's equity has plunged by 71% from the previous quarter and by 37% YoY
The quick ratio has contracted by 47% from the previous quarter and by 5% YoY
Key stats
What are the main financial stats of RNAZ
Market
Valuations
Earnings
Shares outstanding
17.27M
Market cap
$6.37M
Enterprise value
$3.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.85
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$17.84M
EBITDA
-$17.27M
Free cash flow
-$15.46M
Per share
Balance sheet
Liquidity
EPS
-$98.22
Free cash flow per share
-$2.19
Book value per share
$0.2
Revenue per share
$0
TBVPS
$0.68
Total assets
$4.82M
Total liabilities
$3.5M
Debt
$227,246
Equity
$1.32M
Working capital
$884,107
Debt to equity
0.17
Current ratio
1.25
Quick ratio
0.96
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-260.3%
Return on equity
-597.5%
Return on invested capital
N/A
Return on capital employed
-1,348.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNAZ stock price
How has the Transcode Therapeutics stock price performed over time
Intraday
27.17%
1 week
41.96%
1 month
38.33%
1 year
-98.43%
YTD
-94.4%
QTD
-63.49%
Financial performance
How have Transcode Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$17.79M
Net income
-$17.91M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 13% YoY
Transcode Therapeutics's net income has decreased by 5% from the previous quarter but it has increased by 3.6% YoY
Growth
What is Transcode Therapeutics's growth rate over time
Valuation
What is Transcode Therapeutics stock price valuation
P/E
N/A
P/B
1.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 93% YoY and by 59% QoQ
Transcode Therapeutics's equity has plunged by 71% from the previous quarter and by 37% YoY
The price to book (P/B) is 28% lower than the last 4 quarters average of 2.0
Efficiency
How efficient is Transcode Therapeutics business performance
The company's return on equity fell by 12% QoQ and by 7% YoY
The company's return on assets fell by 9% QoQ and by 9% YoY
Dividends
What is RNAZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNAZ.
Financial health
How did Transcode Therapeutics financials performed over time
The total assets is 38% more than the total liabilities
The current ratio has contracted by 50% from the previous quarter and by 10% YoY
The quick ratio has contracted by 47% from the previous quarter and by 5% YoY
Transcode Therapeutics's debt is 83% less than its equity
Transcode Therapeutics's debt to equity has soared by 143% from the previous quarter but it has decreased by 47% YoY
Transcode Therapeutics's equity has plunged by 71% from the previous quarter and by 37% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.